JAK Inhibitors Taking on Psoriatic Arthritis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases.Clinical reviews in allergy & immunology · 2021
   Review
2. Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.World journal of clinical cases · 2020
   Article
3. Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives.Psoriasis (Auckland, N.Z.) · 2019
   Article
4. Psoriasis: A STAT3-Centric View.International journal of molecular sciences · 2018
   Review

Corrections and comments

• Comment on
  Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.2017
• Comment on
  Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.2017

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as